Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
8.49
+0.14 (1.68%)
Nov 22, 2024, 4:00 PM EST - Market closed
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for GLUE stock have an average target of 14.67, with a low estimate of 11 and a high estimate of 17. The average target predicts an increase of 72.79% from the current stock price of 8.49.
Analyst Consensus: Buy
* Price targets were last updated on Sep 12, 2024.
Analyst Ratings
The average analyst rating for GLUE stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +29.56% | Sep 12, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +100.24% | Aug 12, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $16 | Buy | Reiterates | $16 | +88.46% | Jun 28, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +29.56% | May 22, 2024 |
| Wedbush | Wedbush | Buy Initiates $11 | Buy | Initiates | $11 | +29.56% | Feb 15, 2024 |
Financial Forecast
Revenue This Year
15.57M
Revenue Next Year
4.08M
from 15.57M
Decreased by -73.79%
EPS This Year
-1.81
from -2.63
EPS Next Year
-1.53
from -1.81
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.1M | 21.0M | 81.9M | ||
| Avg | 15.6M | 4.1M | 19.4M | ||
| Low | 980,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 34.9% | 1,907.4% | ||
| Avg | - | -73.8% | 375.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.50 | -0.92 | -1.00 | ||
| Avg | -1.81 | -1.53 | -1.69 | ||
| Low | -2.01 | -1.83 | -2.82 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.